Æó¾ÏȯÀÚ¿¡¼­ ¹æ»ç¼± Æó·Å ¿¹ÃøÀ» À§ÇÑ Ç÷Àå Cytokine ÃøÁ¤
The Measurements of Plasma Cytokines in Radiation-induced Pneumonitis in Lung Cancer Patients

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2000³â 18±Ç 4È£ p.314 ~ p.320

Çã¿øÁÖ(Hur Won-Joo) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
À±¼±¹Î(Youn Seon-Min) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
ÀÌÇü½Ä(Lee Hyung-Sik) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
¾ç±¤¸ð(Yang Gwang-Mo) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
½Å°ÇÈ£(Sin Geun-Ho) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
¼ÕÃáÈñ(Son Choon-Hee) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÇÑÁø¿µ(Han Jin-Young) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®Çб³½Ç
À̱Ⳳ(Lee Ki-Nam) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ Áø´Ü¹æ»ç¼±Çб³½Ç
Á¤¹ÎÈ£(Jung Min-Ho) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇ°úÇבּ¸¿ø

Abstract

¸ñ Àû : Æó¾ÏÀ¸·Î È®ÁøµÇ¾î ±ÙÄ¡Àû ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº ȯÀÚ¿¡¼­ ¹æ»ç¼±Æó·ÅÀÌ ¹ß»ýÇÒ ¼ö ÀÖ´Â À§Ç豺À» »çÀü¿¡ ¿¹ÃøÇØ º¸°íÀÚ Ç÷Àå³» TGF-¥â1, TNF-¥á, IL-6ÀÇ ³óµµ¸¦ ÃøÁ¤ÇÏ¿© Æó·Å ¹ß»ý°úÀÇ »ó°ü°ü°è¸¦ ºÐ¼®ÇÏ°íÀÚ ÇÏ¿´´Ù.

Àç·á ¹× ¹æ¹ý : 1998³â 5¿ùºÎÅÍ 1999³â 7¿ù±îÁö Æó¾ÏÀ¸·Î È®ÁøµÇ¾î ±ÙÄ¡Àû ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº 17¸íÀÇ È¯ÀÚ(ºñ¼Ò¼¼Æ÷¾Ï 11¸í, ¼Ò¼¼Æ÷¾Ï 6¸í)À» ´ë»óÀ¸·Î ÇÏ¿´´Ù. ¹æ»ç¼± Ä¡·á´Â ÁÖ 5ȸ ¸ÅÀÏ 1.8 Gy¾¿ ½Ç½ÃÇÏ¿´°í ºñ¼Ò¼¼Æ÷¾Ï°ú ¼Ò¼¼Æ÷¾Ï¿¡¼­ °¢°¢ Æò±Õ 60 Gy¿Í 54 Gy¸¦ Á¶»çÇÏ¿´´Ù. ¸ðµç ȯÀÚ¿¡¼­ ¹æ»ç¼±Ä¡·á Àü, ¹æ»ç¼±Ä¡·á Áß ÁÖ 1ȸ, Ä¡·á ÈÄ ÃßÀû°üÂû·Î ³»¿ø½Ã¸¶´Ù Ç÷¾×À» äÃëÇÏ¿© Ç÷Àå TGF-¥â1, TNF-¥á ¹× IL-6ÀÇ ¾çÀ» ELISA¹ýÀ¸·Î ÃøÁ¤ÇÏ¿´´Ù. ¸ðµç ȯÀÚ¿¡¼­ ´Ü¼øÈäºÎÃÔ¿µ(Ä¡·áÁß ÁÖ1ȸ, Ä¡·á ÈÄ ÃßÀû°üÂû ½Ã¸¶´Ù ÃÔ¿µ) ¹× ¹æ»ç¼± Æó·Å°ú ¿¬°üµÈ Áõ¼¼¸¦ °üÂûÇÏ¿© ¹æ»ç¼± Æó·ÅÀÇ Â¡ÈÄ°¡ ¹ß°ßµÇ¸é Áï½Ã °íÇØ»óµµ ÄÄÇ»ÅÍ ´ÜÃþ ÃÔ¿µ(HRCT)¸¦ ÃÔ¿µÇÏ¿© ¹æ»ç¼± Æó·Å ¹ß»ý¿©ºÎ¸¦ È®ÁøÇÏ°íÀÚ ÇÏ¿´´Ù.

°á °ú : 17¸íÀÇ È¯ÀÚ Áß 13¸í¿¡¼­ ¹æ»ç¼± Æó·Å°ú ¿¬°üµÈ Áõ¼¼°¡ ¹ßÇöµÇ¾ú°í ´Ü¼ø ÈäºÎ ÃÔ¿µ°ú °íÇØ»óµµ ÄÄÇ»ÅÍ ´ÜÃþ ÃÔ¿µ¿¡¼­ À̸¦ È®ÀÎÇÒ ¼ö ÀÖ¾ú´Ù. ¹æ»ç¼± Æó·ÅÀÌ ¹ß»ýÇÑ È¯ÀÚ¿¡¼­ ÃøÁ¤ÇÑ TGF-¥â1ÀÇ °æ¿ì Ư¡ÀûÀÎ ¼öÄ¡ º¯È­¸¦ º¸¿© Ä¡·á Àü Æò±Õ°ªÀº 38.45 ng/ml·Î ¹æ»ç¼± Æó·ÅÀÌ ¹ß»ýÇÏÁö ¾ÊÀº ±º¿¡ ºñÇØ »ó½ÂµÇ¾î ³ªÅ¸³µ°í(22.77 ng/ml) ¹æ»ç¼±Ä¡·á Áß 13.66 ng/mlÀÇ Æò±Õ°ªÀ» º¸ÀÎ ÈÄ ´Ù½Ã Á¡ÁøÀûÀ¸·Î »ó½ÂÇÏ¿© Ä¡·á 2¡­4ÁÖ ÈıîÁö Æò±Õ 60.63 ng/ml·Î »ó½ÂµÇ¾î À¯ÁöµÇ¾ú°í ÀÌ ¼öÄ¡´Â Æó·ÅÀÌ ¹ß»ýÇÏÁö ¾ÊÀº ±º°ú ºñ±³ÇÒ ¶§(12.77 ng/ml) Åë°èÀûÀ¸·Î Àǹ̰¡ ÀÖ¾ú´Ù( p< 0.05). TNF-¥á¿Í IL-6ÀÇ ¼öÄ¡µµ ¹æ»ç¼± Æó·Å±º¿¡¼­ ´õ ³ô°Ô ÃøÁ¤µÇ¾úÀ¸³ª ¼öÄ¡º¯È­ÀÇ ¾ç»óÀº Ư¡ÀûÀÌÁö ¸øÇÏ¿´À¸¸ç Åë°èÇÐÀû Àǹ̵µ ãÀ» ¼ö ¾ø¾ú´Ù.

°á ·Ð : ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº Æó¾ÏȯÀÚ¿¡¼­ Ä¡·á Àü°ú Ä¡·á ±â°£ Áß ¹× Ä¡·á ÈÄ ÃøÁ¤ÇÑ Ç÷Àå TGF-¥â1,ÀÇ ¼öÄ¡´Â ÇâÈÄ ¹æ»ç¼± Æó·ÅÀÌ ¹ß»ýÇÒ À§Ç豺À» ¿¹ÃøÇÒ ¼ö ÀÖ´Â ÁöÇ¥·Î »ç¿ëÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î »ç·áµÈ´Ù.
Purpose : To investigate whether changes in plasma concentrations of transforming growth factor-¥â1 (TGF-¥â1), tumor necrosis factor-alpha (TNF-¥á) and interleukin-6 (IL-6) could be used to identify the development of radiation-induced pneumonitis in the lung cancer patients.

Methods and Materials : Seventeen patients with lung cancer (11 NSCLC, 6 SCLC) were enrolled in a prospective study designed to evaluate clinical and molecular biologic correlation of radiation-induced pneumonitis. The study began in May 1998 and completed in July 1999. All patients were treated with radiotherapy with curative intent : 1.8 Gy per day, 5 fractions per week. Serial measurements of plasma TGF-¥â1, TNF-¥á and IL-6 were obtained in all patients before, weekly during radiotherapy and at each follow-up visits after completion of treatment. These measurements were quantified using enzyme linked immunosorbent assay (ELISA). All patients were evaluated for signs and symptoms of pneumonitis at each follow-up visit after completion of radiotherapy. High resolution CT (HRCT) scans were obtained when signs and symptoms of pneumonitis were developed after completion of radiotherapy.

Results : Thirteen patients eventually developed signs and symptoms of clinical pneumonitis while four patients did not. TGF-¥â1 levels were elevated in all 13 patients with pneumonitis, which showed characteristic pattern of elevation (38.45 ng/ml at pretreatment, 13.66 ng/ml during radiotherapy, then 60.63 ng/ml at 2-4 weeks after completion of radiotherapy). The levels of TNF-¥á and IL-6 were also elevated in the group of patients who developed pneumonitis but the pattern was not characteristic.

Conclusions : Changes in plasma TGF¥â-1 levels before, during and after radiotherapy appears to be a useful means by which to identify patients at risk for the development of symptomatic pneumonitis. Other cytokines like TNF-¥á and IL-6 shows no meaningful changes in association with radiation pneumonitis.

Å°¿öµå

Æó¾Ï, ¹æ»ç¼±Ä¡·á, ¹æ»ç¼±Æó·Å, »çÀÌÅäÄ«ÀÎ, Radiotherapy, Radiation Pneumonitis, Cytokines,
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
Changes in plasma TGF¥â-1 levels before, during and after radiotherapy appears to be a useful means by which to identify patients at risk for the development of symptomatic pneumonitis.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå